Masitinib (BioDeep_00000180658)

   

human metabolite blood metabolite


代谢物信息卡片


N-(4-methyl-3-{[4-(pyridin-3-yl)-2,3-dihydro-1,3-thiazol-2-ylidene]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide

化学式: C28H30N6OS (498.220169)
中文名称: 马赛替尼
谱图信息: 最多检出来源 Homo sapiens(blood) 97.78%

分子结构信息

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5
InChI: InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)

描述信息

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

12 个代谢物同义名

N-(4-methyl-3-{[4-(pyridin-3-yl)-2,3-dihydro-1,3-thiazol-2-ylidene]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; N-(4-methyl-3-{[4-(pyridin-3-yl)-3H-1,3-thiazol-2-ylidene]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; 4-((4-Methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide; Masitinib mesylate; Masitinib (AB1010); Kinavet ca-1; Masitinib; Masatinib; Masivet; AB-1010; AB 1010; AB1010



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(4)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Nir Drayman, Jennifer K DeMarco, Krysten A Jones, Saara-Anne Azizi, Heather M Froggatt, Kemin Tan, Natalia Ivanovna Maltseva, Siquan Chen, Vlad Nicolaescu, Steve Dvorkin, Kevin Furlong, Rahul S Kathayat, Mason R Firpo, Vincent Mastrodomenico, Emily A Bruce, Madaline M Schmidt, Robert Jedrzejczak, Miguel Á Muñoz-Alía, Brooke Schuster, Vishnu Nair, Kyu-Yeon Han, Amornrat O'Brien, Anastasia Tomatsidou, Bjoern Meyer, Marco Vignuzzi, Dominique Missiakas, Jason W Botten, Christopher B Brooke, Hyun Lee, Susan C Baker, Bryan C Mounce, Nicholas S Heaton, William E Severson, Kenneth E Palmer, Bryan C Dickinson, Andrzej Joachimiak, Glenn Randall, Savaş Tay. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science (New York, N.Y.). 2021 08; 373(6557):931-936. doi: 10.1126/science.abg5827. [PMID: 34285133]
  • Ulises Martínez-Ortega, Diego I Figueroa-Figueroa, Francisco Hernández-Luis, Rodrigo Aguayo-Ortiz. In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease. ChemMedChem. 2021 08; 16(15):2339-2344. doi: 10.1002/cmdc.202100375. [PMID: 34142459]
  • M Kuijlaars, J Helm, A McBrearty. Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019). The Journal of small animal practice. 2021 Aug; 62(8):646-654. doi: 10.1111/jsap.13305. [PMID: 33634470]
  • Zi Ping Leong, Yoshiaki Hikasa. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. Vascular pharmacology. 2019 Nov; 122-123(?):106599. doi: 10.1016/j.vph.2019.106599. [PMID: 31629919]
  • Anne M Filppula, Tiffany M Mustonen, Janne T Backman. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions. Basic & clinical pharmacology & toxicology. 2018 Dec; 123(6):739-748. doi: 10.1111/bcpt.13088. [PMID: 29956478]
  • Phillip A Wages, Hye-Young H Kim, Zeljka Korade, Ned A Porter. Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol. Journal of lipid research. 2018 10; 59(10):1916-1926. doi: 10.1194/jlr.m086991. [PMID: 30087204]
  • Lauren Devine, David J Polzin. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog. The Canadian veterinary journal = La revue veterinaire canadienne. 2016 Jul; 57(7):752-6. doi: NULL. [PMID: 27429464]
  • Rishil J Kathawala, Kamlesh Sodani, Kang Chen, Atish Patel, Alaa H Abuznait, Nagaraju Anreddy, Yue-Li Sun, Amal Kaddoumi, Charles R Ashby, Zhe-Sheng Chen. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Molecular cancer therapeutics. 2014 Mar; 13(3):714-23. doi: 10.1158/1535-7163.mct-13-0743. [PMID: 24431074]
  • M R Brown, R E Cianciolo, M B Nabity, C A Brown, F J Clubb, G E Lees. Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog. Journal of veterinary internal medicine. 2013 Nov; 27(6):1622-6. doi: 10.1111/jvim.12189. [PMID: 24020652]
  • Sophie Georgin-Lavialle, Ludovic Lhermitte, Felipe Suarez, Ying Yang, Sébastien Letard, Katia Hanssens, Frédéric Feger, Amédée Renand, Chantal Brouze, Danielle Canioni, Vahid Asnafi, Marie-Olivia Chandesris, Achille Aouba, Paul Gineste, Elizabeth Macintyre, Colin D Mansfield, Alain Moussy, Yves Lepelletier, Patrice Dubreuil, Olivier Hermine. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. European journal of haematology. 2012 Jul; 89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. [PMID: 22324351]
  • François Bellamy, Thomas Bader, Alain Moussy, Olivier Hermine. Pharmacokinetics of masitinib in cats. Veterinary research communications. 2009 Dec; 33(8):831-7. doi: 10.1007/s11259-009-9231-6. [PMID: 19533403]